Recent Publications

Taatjes, DJ; Tjian, R. Structure and function of CRSP/Med2: a promoter-selective transcriptional coactivator complex. Mol Cell. 2004, 14, 675-683.

Taatjes, DJ; Schneider-Poetsch, T; Tjian, R. Distinct conformational states of nuclear receptor−bound CRSP−Med complexes. Nat Struct Mol Biol. 2004, 11, 664-671.

Taatjes, DJ; Marr, MT; Tjian, R. Regulatory diversity among metazoan co-activator complexes. Nat Rev Mol Cell Biol. 2004, 5, 403-410.

Näär;, AM;Taatjes, DJ; Zhai, W; Tjian, R. Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. Genes Dev. 2002, 16, 1339-1344.

Taatjes, DJ; Näär;, AM; Andel, F; Nogales, E; Tjian, R. Structure, function, and activator-induced conformations of the CRSP coactivator. Science 2002, 295, 1058-1062.

All Publications

Taatjes, DJ; Gaudiano, G; Resing, K; Koch, TH. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 1996, 39, 4135-4138.

Taatjes, DJ; Gaudiano, G; Resing, K; Koch, TH. A redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs, Adriamycin and Daunomycin.  J. Med. Chem. 1997, 40, 1276-1286.

Fenick, DJ; Taatjes, DJ; Koch, TH. Doxoform and Daunoform: anthrcycline-formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem. 1997, 40, 2452-2461.

Taatjes, DJ; Gaudiano, G; Koch, TH. Production of formaldehyde and DNA-adriamycin or –daunomycin adducts, initiated through redox chemistry of DTT/iron, xanthine oxidase/NADH/iron, or glutathione/iron. Chem. Res. Toxicol. 1997, 10, 953-961.

Taatjes, DJ; Fenick, DJ; Gaudiano, G; Koch, TH. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer.  Curr. Pharm. Des. 1998, 4, 217-232.

Taatjes, DJ; Fenick, DJ; Koch, TH. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate, toxic to resistant tumor cells.  J. Med. Chem. 1998, 41, 1306-1314.

Taatjes, DJ; Koch, TH. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.  Anticancer Res. 1999, 19, 1201-1208.

Podell, E; Harrington, D; Taatjes, DJ; Koch, TH. Crystal structure of Epidoxorubicin-formaldehyde virtual crosslink to DNA and evidence of its formation in human breast cancer cells. Acta Cryst. 1999, D55, 1516-1523.

Taatjes, DJ; Fenick, DJ; Koch, TH. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol. 1999, 12, 588-596. [Cover]

Kato, S; Burke, PJ; Fenick, DJ; Taatjes, DJ; Bierbaum, VM; Koch, TH. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs. Chem. Res. Toxicol. 2000, 13, 509-516.

Taatjes, DJ; Koch, TH. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr. Med. Chem. 2001, 8, 15-29.

Dernell, WS; Powers, BE; Taatjes, DJ; Cogan, P; Gaudiano, G; Koch, TH. Evaluation of the epidoxorubicin-formaldehyde conjugate, Epidoxoform, in a mouse mammary carcinoma model. Cancer Invest. 2002, 20, 712-723.

Taatjes, DJ; Näär, AM; Andel, F; Nogales, E; Tjian, R. Structure, function, and activator-induced conformations of the CRSP coactivator. Science 2002, 295, 1058-1062.

Näär, AM;Taatjes, DJ; Zhai, W; Tjian, R. Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. Genes Dev. 2002, 16, 1339-1344.

Taatjes, DJ; Marr, MT; Tjian, R. Regulatory diversity among metazoan co-activator complexes. Nat Rev Mol Cell Biol. 2004, 5, 403-410.

Taatjes, DJ; Schneider-Poetsch, T; Tjian, R. Distinct conformational states of nuclear receptor-bound CRSP−Med complexes. Nat Struct Mol Biol. 2004, 11, 664-671.

Taatjes, DJ; Tjian, R. Structure and function of CRSP/Med2: a promoter-selective transcriptional coactivator complex. Mol Cell. 2004, 14, 675-683.

Patents

"New anthracycline anti-tumor drugs with enhanced cytotoxicity: compounds, compositions, and methods." Dylan J. Taatjes, David J. Fenick, Tad H. Koch Inventors, US Patent No. 6,677,309.